The Truth Behind Repatha's Device Discontinuation
Many patients have been surprised by recent announcements regarding changes to the availability of certain Repatha injection systems. It is important to clarify that Amgen has not discontinued the medication Repatha (evolocumab) as a whole. The drug remains a viable treatment option for high cholesterol, particularly for those with familial hypercholesterolemia or established cardiovascular disease. The changes are strictly related to the delivery devices, with the company focusing on a more standardized and user-friendly approach.
The End of the Pushtronex System
Amgen officially discontinued the Repatha Pushtronex System, an on-body infusor, on June 30, 2024. The company cited a desire to uphold high standards for patient experience as the primary reason for this decision. For patients accustomed to this system, it requires a transition to one of the other available options.
Phasing Out the Prefilled Syringe
In addition to the Pushtronex, Amgen also plans to discontinue the standard prefilled syringe for Repatha in mid-2025. This move further consolidates the delivery methods, encouraging the use of the Repatha SureClick® autoinjector, which is the most widely prescribed option. The strategy aims to simplify the product portfolio and improve overall patient usability.
Why Amgen Chose to Streamline Delivery
The manufacturer's rationale for discontinuing the Pushtronex and standard syringe centered on streamlining its offerings to provide the most optimal patient experience. By focusing on a single primary device—the SureClick autoinjector—the company can dedicate its resources to refining and supporting that system, potentially leading to fewer user errors and a better overall experience.
Prioritizing the SureClick Autoinjector
The Repatha SureClick autoinjector is the company's preferred delivery system for most patients. This consolidation allows for more focused support and education around a single device, benefiting both healthcare providers and patients alike.
Accommodating Latex Allergies with New Options
One important consideration was the need to provide alternatives for patients with specific needs. Amgen addressed concerns for individuals with latex allergies by introducing new device presentations that are not made with natural rubber latex. This includes a new latex-free prefilled syringe available in early 2025 and a latex-free SureClick autoinjector expected in limited quantities by April 2025.
How the Discontinuation Affects Patients
Patients currently using a discontinued device will need to consult their healthcare provider for a new prescription. The doctor will determine the most suitable alternative, most often the SureClick autoinjector. While the drug itself remains the same, a new prescription is required to specify the new delivery method.
Comparing Repatha Device Options
| Feature | Discontinued Pushtronex System | Discontinued Prefilled Syringe (Mid-2025) | Available SureClick Autoinjector |
|---|---|---|---|
| Mechanism | On-body infusor for single-dose delivery | Standard manual syringe | Single-dose, push-button autoinjector |
| Dose | 420 mg in one dose | 140 mg | 140 mg |
| Reason for Discontinuation | Improve patient experience; simplify product line | Improve patient experience; consolidate devices | N/A - Remains the primary option |
| Patient Action Required | Transition to alternative; new prescription needed | Transition to alternative; new prescription needed | No action needed if already using |
Alternatives for Repatha Users
For patients who need to transition from a discontinued device, the most likely path is to the Repatha SureClick autoinjector. However, patients who previously used the 420mg Pushtronex dose will need to switch to three consecutive 140mg injections with the new device. For those with latex allergies, new versions of the SureClick and syringe are available or forthcoming.
For those seeking alternatives beyond Repatha itself, other PCSK9 inhibitors are available, such as Praluent (alirocumab). There are also oral medications like statins or cholesterol absorption inhibitors, though these may have different efficacy and are often used in combination with other treatments. Patients should always discuss alternative treatment options with their healthcare provider.
Conclusion: A Shift Towards Simplified Treatment
The discontinuation of certain Repatha delivery devices is a strategic move by Amgen, prioritizing the standardization of patient care around the company's most popular device, the SureClick autoinjector. This was not a safety recall, but rather an evolution in product management. Patients who are affected should consult their doctor to ensure a smooth transition to an alternative, readily available Repatha delivery system. The overall goal is to simplify the injection process and maintain high standards for patients managing their cholesterol. Based on information from the manufacturer's website, Amgen continues to support Repatha treatment with its primary delivery systems and through patient assistance programs.
